Virginia Athena Triant, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 57 | 2024 | 17165 | 3.210 |
Why?
|
Cardiovascular Diseases | 19 | 2024 | 15757 | 1.200 |
Why?
|
HIV | 10 | 2021 | 1579 | 1.170 |
Why?
|
Anti-HIV Agents | 11 | 2023 | 4491 | 0.970 |
Why?
|
Epidemics | 2 | 2021 | 510 | 0.770 |
Why?
|
Myocardial Infarction | 7 | 2024 | 11891 | 0.600 |
Why?
|
HIV Protease Inhibitors | 1 | 2020 | 432 | 0.580 |
Why?
|
Smoking Cessation | 2 | 2020 | 2064 | 0.540 |
Why?
|
Myocardial Ischemia | 2 | 2017 | 2164 | 0.530 |
Why?
|
CD4 Lymphocyte Count | 6 | 2019 | 2569 | 0.500 |
Why?
|
Stroke | 4 | 2020 | 9962 | 0.500 |
Why?
|
Behavior Therapy | 1 | 2020 | 868 | 0.470 |
Why?
|
Anti-Retroviral Agents | 5 | 2020 | 1779 | 0.470 |
Why?
|
Risk Factors | 35 | 2024 | 74359 | 0.460 |
Why?
|
Atherosclerosis | 3 | 2017 | 3517 | 0.420 |
Why?
|
Smoking | 4 | 2021 | 9073 | 0.420 |
Why?
|
Risk Reduction Behavior | 1 | 2018 | 1109 | 0.400 |
Why?
|
Secondary Prevention | 1 | 2018 | 1548 | 0.400 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1602 | 0.390 |
Why?
|
Carotid Artery Diseases | 4 | 2021 | 883 | 0.380 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2315 | 0.350 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1881 | 0.330 |
Why?
|
Coronary Disease | 2 | 2014 | 5990 | 0.310 |
Why?
|
Viral Load | 8 | 2019 | 3322 | 0.300 |
Why?
|
Brain Ischemia | 1 | 2020 | 3127 | 0.280 |
Why?
|
Risk Assessment | 11 | 2024 | 24123 | 0.280 |
Why?
|
Middle Aged | 44 | 2024 | 220352 | 0.270 |
Why?
|
Humans | 74 | 2024 | 760621 | 0.270 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 282 | 0.270 |
Why?
|
HIV Long-Term Survivors | 2 | 2019 | 121 | 0.260 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4433 | 0.260 |
Why?
|
Africa South of the Sahara | 2 | 2017 | 742 | 0.240 |
Why?
|
Adult | 31 | 2024 | 219994 | 0.230 |
Why?
|
Hospitalization | 5 | 2021 | 10790 | 0.220 |
Why?
|
Dideoxynucleosides | 1 | 2023 | 132 | 0.220 |
Why?
|
Cerebral Hemorrhage | 1 | 2014 | 2660 | 0.210 |
Why?
|
Male | 41 | 2024 | 359744 | 0.210 |
Why?
|
Subacute Care | 2 | 2023 | 177 | 0.210 |
Why?
|
Female | 44 | 2024 | 391270 | 0.200 |
Why?
|
Botswana | 3 | 2023 | 1040 | 0.200 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2696 | 0.190 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 26 | 0.190 |
Why?
|
Oxazines | 1 | 2023 | 341 | 0.190 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 279 | 0.180 |
Why?
|
Mass Screening | 1 | 2017 | 5423 | 0.180 |
Why?
|
Incidence | 8 | 2021 | 21392 | 0.180 |
Why?
|
Death, Sudden, Cardiac | 2 | 2019 | 1572 | 0.180 |
Why?
|
Purpura | 1 | 2021 | 116 | 0.180 |
Why?
|
Boston | 4 | 2020 | 9280 | 0.170 |
Why?
|
California | 1 | 2024 | 1416 | 0.170 |
Why?
|
Hepatitis C | 2 | 2022 | 1579 | 0.170 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2022 | 621 | 0.170 |
Why?
|
Case Management | 1 | 2021 | 272 | 0.170 |
Why?
|
Pressure Ulcer | 1 | 2021 | 156 | 0.170 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3839 | 0.170 |
Why?
|
Cohort Studies | 12 | 2021 | 41335 | 0.170 |
Why?
|
New York City | 1 | 2021 | 724 | 0.160 |
Why?
|
Microcirculation | 1 | 2023 | 1278 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 533 | 0.160 |
Why?
|
Inpatients | 2 | 2020 | 2581 | 0.160 |
Why?
|
Heart Failure | 7 | 2020 | 11847 | 0.160 |
Why?
|
Antigens, CD | 3 | 2018 | 4000 | 0.160 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2018 | 1894 | 0.160 |
Why?
|
Patient Discharge | 2 | 2023 | 3476 | 0.150 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2825 | 0.150 |
Why?
|
Pyridones | 1 | 2023 | 792 | 0.150 |
Why?
|
Sex Factors | 3 | 2024 | 10547 | 0.150 |
Why?
|
Case-Control Studies | 6 | 2023 | 22053 | 0.150 |
Why?
|
Decision Support Techniques | 2 | 2018 | 2001 | 0.140 |
Why?
|
Aged | 23 | 2023 | 169152 | 0.140 |
Why?
|
Myocardium | 2 | 2020 | 4700 | 0.140 |
Why?
|
Adipose Tissue | 2 | 2020 | 3301 | 0.140 |
Why?
|
Exanthema | 1 | 2021 | 504 | 0.140 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 223 | 0.130 |
Why?
|
Fractures, Bone | 1 | 2008 | 2041 | 0.130 |
Why?
|
Accidental Falls | 1 | 2024 | 1056 | 0.130 |
Why?
|
Uganda | 5 | 2021 | 1324 | 0.130 |
Why?
|
E-Selectin | 1 | 2018 | 576 | 0.130 |
Why?
|
Hormones | 1 | 2019 | 867 | 0.130 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 691 | 0.130 |
Why?
|
Obesity | 5 | 2022 | 12922 | 0.130 |
Why?
|
Nitrates | 1 | 2016 | 264 | 0.120 |
Why?
|
Risk | 2 | 2017 | 9631 | 0.120 |
Why?
|
Hepacivirus | 2 | 2022 | 1334 | 0.120 |
Why?
|
Disease Management | 2 | 2017 | 2514 | 0.120 |
Why?
|
Protease Inhibitors | 1 | 2018 | 755 | 0.120 |
Why?
|
Continuity of Patient Care | 1 | 2021 | 1066 | 0.120 |
Why?
|
Prevalence | 6 | 2023 | 15687 | 0.120 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2018 | 1126 | 0.120 |
Why?
|
Arteritis | 1 | 2016 | 162 | 0.120 |
Why?
|
Risk Management | 1 | 2017 | 558 | 0.110 |
Why?
|
Aftercare | 1 | 2020 | 916 | 0.110 |
Why?
|
Monocytes | 2 | 2020 | 2575 | 0.110 |
Why?
|
United States | 10 | 2022 | 72461 | 0.110 |
Why?
|
Coronary Artery Disease | 4 | 2020 | 6659 | 0.110 |
Why?
|
Pericardium | 1 | 2018 | 675 | 0.110 |
Why?
|
Piperazines | 1 | 2023 | 2525 | 0.110 |
Why?
|
Patient Readmission | 4 | 2023 | 3323 | 0.110 |
Why?
|
Fibrosis | 1 | 2020 | 2042 | 0.100 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 859 | 0.100 |
Why?
|
Time Factors | 4 | 2021 | 40165 | 0.100 |
Why?
|
Interleukin-6 | 2 | 2022 | 3215 | 0.100 |
Why?
|
Buprenorphine | 1 | 2020 | 654 | 0.100 |
Why?
|
American Heart Association | 1 | 2017 | 1081 | 0.100 |
Why?
|
Diazepam | 1 | 2013 | 215 | 0.100 |
Why?
|
Drug Interactions | 1 | 2016 | 1428 | 0.100 |
Why?
|
Preventive Health Services | 1 | 2017 | 570 | 0.100 |
Why?
|
Triglycerides | 1 | 2019 | 2476 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2017 | 782 | 0.100 |
Why?
|
Inflammation | 3 | 2016 | 10756 | 0.100 |
Why?
|
Hypertension | 3 | 2023 | 8594 | 0.100 |
Why?
|
Longitudinal Studies | 4 | 2021 | 14495 | 0.100 |
Why?
|
Comorbidity | 4 | 2020 | 10551 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2018 | 1817 | 0.090 |
Why?
|
Midazolam | 1 | 2013 | 267 | 0.090 |
Why?
|
Cardiomyopathies | 2 | 2020 | 1952 | 0.090 |
Why?
|
Length of Stay | 2 | 2023 | 6479 | 0.090 |
Why?
|
Prognosis | 3 | 2024 | 29658 | 0.090 |
Why?
|
Diabetic Angiopathies | 1 | 2015 | 822 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2023 | 80372 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 25942 | 0.090 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 700 | 0.090 |
Why?
|
Sleep Apnea Syndromes | 1 | 2018 | 974 | 0.090 |
Why?
|
Aging | 4 | 2022 | 8651 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1523 | 0.090 |
Why?
|
Heart | 2 | 2020 | 4393 | 0.080 |
Why?
|
Anesthetics, Intravenous | 1 | 2013 | 397 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58995 | 0.080 |
Why?
|
Antiviral Agents | 2 | 2022 | 3061 | 0.080 |
Why?
|
Anticholesteremic Agents | 1 | 2016 | 987 | 0.080 |
Why?
|
International Classification of Diseases | 1 | 2014 | 894 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3361 | 0.080 |
Why?
|
Dementia | 1 | 2023 | 2649 | 0.080 |
Why?
|
Delivery of Health Care | 4 | 2022 | 5325 | 0.080 |
Why?
|
Hypoglycemia | 1 | 2015 | 888 | 0.080 |
Why?
|
Plaque, Atherosclerotic | 1 | 2020 | 1518 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2017 | 878 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6360 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2017 | 2197 | 0.080 |
Why?
|
Diabetes Mellitus | 2 | 2017 | 5889 | 0.070 |
Why?
|
Emigrants and Immigrants | 1 | 2014 | 539 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2018 | 2128 | 0.070 |
Why?
|
Medical Informatics | 1 | 2014 | 732 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3736 | 0.070 |
Why?
|
Blood Pressure | 2 | 2023 | 8525 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3224 | 0.070 |
Why?
|
HIV-1 | 3 | 2019 | 6849 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5877 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7806 | 0.060 |
Why?
|
Young Adult | 5 | 2018 | 58741 | 0.060 |
Why?
|
Adolescent | 5 | 2018 | 87810 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2020 | 2138 | 0.060 |
Why?
|
Colonoscopy | 1 | 2013 | 1387 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 2003 | 0.060 |
Why?
|
Dideoxyadenosine | 1 | 2023 | 14 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2022 | 65017 | 0.060 |
Why?
|
Calcinosis | 1 | 2012 | 1476 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2016 | 3201 | 0.060 |
Why?
|
Pilot Projects | 1 | 2017 | 8555 | 0.060 |
Why?
|
Databases, Factual | 1 | 2018 | 8035 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 363 | 0.050 |
Why?
|
Cyclopropanes | 1 | 2023 | 431 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5496 | 0.050 |
Why?
|
Asthma | 1 | 2020 | 6172 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2020 | 4775 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15289 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3334 | 0.050 |
Why?
|
Age Distribution | 1 | 2007 | 2893 | 0.050 |
Why?
|
Alanine | 1 | 2023 | 606 | 0.050 |
Why?
|
Blood Sedimentation | 1 | 2022 | 234 | 0.050 |
Why?
|
Drug Substitution | 1 | 2023 | 296 | 0.050 |
Why?
|
Anticoagulants | 1 | 2016 | 4897 | 0.050 |
Why?
|
Logistic Models | 2 | 2020 | 13314 | 0.050 |
Why?
|
Prone Position | 1 | 2021 | 196 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12531 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2022 | 418 | 0.040 |
Why?
|
Government Programs | 1 | 2022 | 280 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2021 | 499 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 597 | 0.040 |
Why?
|
Chronic Disease | 1 | 2014 | 9287 | 0.040 |
Why?
|
Acute Disease | 1 | 2009 | 7269 | 0.040 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2023 | 571 | 0.040 |
Why?
|
Cause of Death | 2 | 2019 | 3725 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2022 | 1600 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18416 | 0.040 |
Why?
|
Drug Combinations | 1 | 2023 | 2025 | 0.040 |
Why?
|
Coronary Circulation | 1 | 2023 | 1577 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11903 | 0.040 |
Why?
|
Models, Statistical | 1 | 2011 | 5075 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6853 | 0.030 |
Why?
|
Registries | 2 | 2014 | 8469 | 0.030 |
Why?
|
Health Facilities | 1 | 2021 | 578 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1242 | 0.030 |
Why?
|
Hospitals, General | 1 | 2020 | 795 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12293 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2022 | 830 | 0.030 |
Why?
|
Opiate Substitution Treatment | 1 | 2020 | 436 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2009 | 12159 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 6180 | 0.030 |
Why?
|
Feces | 1 | 2022 | 1455 | 0.030 |
Why?
|
Cocaine-Related Disorders | 1 | 2019 | 460 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9467 | 0.030 |
Why?
|
Stroke Volume | 2 | 2019 | 5523 | 0.030 |
Why?
|
Biostatistics | 1 | 2016 | 164 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 587 | 0.030 |
Why?
|
Cognition | 2 | 2023 | 6957 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2018 | 951 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 13981 | 0.030 |
Why?
|
RNA, Viral | 1 | 2022 | 2838 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1328 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2722 | 0.030 |
Why?
|
Coronary Vessels | 1 | 2023 | 3112 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14660 | 0.020 |
Why?
|
Treatment Failure | 1 | 2018 | 2648 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1791 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1940 | 0.020 |
Why?
|
Reference Standards | 1 | 2014 | 1004 | 0.020 |
Why?
|
Disease Progression | 2 | 2021 | 13502 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2754 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 3765 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21025 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4107 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2622 | 0.020 |
Why?
|
Data Mining | 1 | 2014 | 553 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20080 | 0.020 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1499 | 0.020 |
Why?
|
Body Composition | 1 | 2018 | 2419 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2015 | 895 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9716 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3164 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8803 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6498 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6465 | 0.020 |
Why?
|
Angiography | 1 | 2012 | 1605 | 0.020 |
Why?
|
Mortality | 1 | 2018 | 2916 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3880 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5425 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 54303 | 0.020 |
Why?
|
Rural Population | 1 | 2016 | 2268 | 0.020 |
Why?
|
Language | 1 | 2014 | 1533 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3763 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 12960 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15840 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 36290 | 0.010 |
Why?
|
Cytokines | 1 | 2015 | 7343 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8624 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36060 | 0.010 |
Why?
|
Primary Health Care | 1 | 2015 | 4647 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39261 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20509 | 0.010 |
Why?
|